The Latest Breaking News on Pharma

European countries could stretch out limited supplies of the monkeypox vaccine by administering smaller doses of the shot, the European Medicines Agency (EMA) said on Friday.

The European Medicines Agency said a smaller dose of the monkeypox vaccine appears to still be effective and can be used to stretch the current supply by five times, echoing a recommendation made earlier this month by the U.S. Food and Drug Administration

PharmAla Biotech Holdings Inc, the biotech company producing MDXX class molecules has released a large-scale batch of its proprietary MDMA API, “Laneo,” becoming the first publicly-traded venture to produce the drug within Good Manufacturing Processes (GMP) in such a major amount.

Renowned biopharmaceutical company AbbVie (ABBV) continued its business momentum in the second quarter with considerable progress for its new products and indications. Moreover, the company is well-positioned to benefit from significant advances across its pipeline. Given its diversified business model, strong financials, high profitability, discounted valuation, and solid growth prospects,…

Despite the market volatility and odds of a recession, the pharma industry is well-positioned to grow due to the aging global population and the increasing chronic diseases. Therefore, investing in quality pharma stocks Pfizer (PFE) and Merck & Co. (MRK) could be wise. Read more.

Petitioner cites case of Dolo 650, says any dosage beyond 500 mg is outside regulation

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has initiated a new Phase 3 trial to investigate the efficacy and safety of Epidiolex (cannabidiol), known as Epidyolex in Europe, in children and adolescents with e

Endo International, one of the nation's larger opioid makers and with U.S. headquarters in Malvern, filed for bankruptcy protection in Manhattan on Tuesday, beset by $9.5 billion in total debt and threatened by thousands of opioid lawsuits.

Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom.